Mounjaro Effectiveness: Long-Term Weight Loss Sustained Over 3 Years

Understanding Long-Term Mounjaro Effectiveness 

A groundbreaking study supporting long-term Mounjaro effectiveness has seen participants maintain significant weight reduction compared with Wegovy. 

The latest results from the SURMOUNT-5 trial published in The New England Journal of Medicine, have shown that individuals taking Mounjaro (tirzepatide) sustained an average weight loss of 20.2% over 3 years compared with Wegovy (semaglutide) at 13.7%. 

Researchers who led this Mounjaro trial said both drugs had a role, but Mounjaro may help those with the most weight to lose. The trial has been highlighted as part of ongoing Mounjaro news, with wide coverage including the BBC and The Guardian. The SURMOUNT-5 study has drawn attention for its groundbreaking findings which reflect the increasing recognition of Mounjaro’s long-term effectiveness and its potential to redefine how weight loss treatment is approached. 

 
SURMOUNT-5 Trial Results 

The SURMOUNT-5 study which is part of ongoing research funded by Eli Lilly included 751 participants who were overweight or obese. The aim of this mounjaro trial was to compare both drugs and demonstrate Mounjaro’s effectiveness over Wegovy. The SURMOUNT-5 trial results demonstrated the following findings: 

• Participants on Mounjaro lost an average of 20.2% weight over 3 years.
• Participants on Wegovy lost an average of 13.7% weight over 3 years. 
  
  
• Participants on Mounjaro reduced their waist size by an average of 18.4 cm over 3 years.
• Participants on Wegovy reduced their waist size by an average of 13 cm over 3 years.
  
  
• Most common adverse events in both treatment groups were gastrointestinal, and most were mild to moderate in severity and occurred primarily during dose escalation, for both Mounjaro and Wegovy. 

 
"Thanks to the latest advancements in obesity management medications, more physicians and patients are witnessing significant weight reduction beyond what they have seen before," said Louis J. Aronne, MD, FACP, DABOM, director of the Comprehensive Weight Control Center and the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medicine who was the principal investigator of SURMOUNT-5 also stated: "The SURMOUNT-5 head-to-head results demonstrated Mounjaro (tirzepatide) led to greater weight reduction compared to Wegovy (semaglutide), providing further evidence to support Mounjaro as an effective option for obesity management." 

 
The Slimming Clinic’s Expert Insight 

Dr. Charlotte Norton, Chief Medical Officer here at The Slimming Clinic says:  
“Weight loss medications such as Mounjaro and Wegovy are effective tools for those who want to lose weight especially when combined with diet and lifestyle changes. This study highlights the considerable weight loss that can be achieved. Having several weight loss medication options provides patients with choice and by consulting with a specialist team like we have at The Slimming Clinic, the right medication for you and your health can be selected. We know these medications have been found to have additional benefits above weight loss including blood sugar control, reduction in addictive behaviours and for Wegovy, a reduction in cardiovascular risk.” 

 
Understanding Mounjaro, Wegovy, and Their Results 

Mounjaro injections work by targeting both GIP and GLP-1 hormone receptors. This dual-action mechanism helps to enhance insulin sensitivity, suppress appetite, and slow digestion. Its effectiveness is especially notable for individuals who have experienced weight regain in the past, offering a powerful tool for long-term weight management. More information about Mounjaro can be found here. 

In contrast, Wegov injections focus solely on the GLP-1 hormone receptor, which plays a central role in regulating appetite and food intake. By mimicking this naturally occurring hormone, Wegovy reduces hunger, increases satiety, and supports lower calorie consumption. Its single-hormone action is clinically proven to facilitate significant weight loss, particularly when paired with healthy lifestyle changes. More information about Wegovy can be found here. 

While recent studies suggest that Mounjaro’s effectiveness may demonstrate greater overall results in sustaining weight loss, Wegovy still offers valuable benefits, especially for patients with underlying health concerns. Notably, GLP-1 medications like Wegovy have been shown to support cardiovascular health. You can learn more in our article on Wegovy and heart health. 

For a detailed comparison between the two treatments, explore our article on Mounjaro vs Wegovy to understand how each option may best support your individual weight loss goals. 

 
Our Patient’s Experience With Mounjaro 

Our patient Nina’s experience echoes the findings of the recent SURMOUNT-5 trial, which highlights long-term Mounjaro effectiveness. After years of struggling to manage her weight through conventional methods, Nina began treatment with Mounjaro and, under medical supervision, experienced steady progress. She not only lost weight but maintained her results over time. Her story is featured in our blog Real Mounjaro Weight Loss Results: Nina's Success Story. See more weight loss success stories here. 

 
Access and Support at The Slimming Clinic 

At The Slimming Clinic, our GMC-registered doctors offer personalised care and guidance for those considering Mounjaro or Wegovy as part of their weight loss journey. 

To learn about which medication is right for you and how it fits into your long-term weight loss journey book a free call back to discuss your options. Our doctors will provide individualised assessments and ensure your treatment is safe, effective, and you are supported at every step.